Navigation Links
Kinex Receives Research Support from the Hong Kong Innovation and Technology Commission (ITC)
Date:8/1/2013

BUFFALO, N.Y., Aug. 1, 2013 /PRNewswire/ -- Kinex Pharmaceuticals is pleased to announce that their application for the Small Entrepreneur Research Assistance Programme has been approved by the Innovation and Technology Commission of Hong Kong.  This financial support will be used to fund Kinex's development of preclinical data on both docetaxel (Taxotere) and doxorubicin (Doxil) when combined with HM30181A, an innovative P-glycoprotein pump inhibitor that converts IV drugs into oral formulations.  Additionally, it will provide the opportunity to work with key opinion leaders in Hong Kong as well as some of the foremost clinics and institutions.  These efforts will further broaden the Orascovery program and is expected to significantly increase Kinex's pipeline portfolio.

The Orascovery program is based on an important platform technology currently co-developed by Hanmi Pharmaceuticals and Kinex, compound HM30181A, a potent and selective P-glycoprotein (PGP) pump inhibitor.  Suppression of the PGP pump allows certain clinically important compounds (such as Paclitaxel and Irinotecan, among others) which would normally be effluxed back into the gastrointestinal tract and excreted, to enter the bloodstream and be bioavailable through oral administration.  Importantly, HM30181A is a very effective PGP inhibitor that is not systemically absorbed.

The Orascovery technology has led to the initiation of clinical trials being conducted with both an oral formulation of paclitaxel (Oraxol), currently in Phase II clinical trials in Korea, and an oral formulation of Irinotecan (Oratecan), which has completed a Phase I clinical trial in Korea. On July 22, Kinex announced that the US FDA had allowed the company's IND for Oraxol.  Trials will begin this fall.

In May of 2013, Kinex licensed the Oraxol and Oratecan rights for Australia and New Zealand to Zenith Technology Corporation (Dunedin, New Zealand).  Zenith Technology Corporation will commit a significant amount of resources to the Oraxol and Oratecan global development programs, providing Kinex and Hanmi Pharmaceuticals additional clinical programs to support the global registration strategy.  

Johnson YN Lau, MD, FRCP, Kinex CEO and Chairman stated, "I am gratified that the Kinex research programs combining HM30181A, a novel P-glycoprotein pump inhibitor, with docetaxel and doxorubicin has received financial support from the Hong Kong Government ITC. This program will strengthen our foot print in Asia and allow us to further leverage the research collaboration between Asia, in particular Hong Kong, and the United States.  These programs have been assigned to our wholly-owned subsidiary Kinex Pharmaceuticals (HK) Limited in our effort to grow our Asian infrastructure."

"The Hong Kong environment provides Kinex with an important source of highly skilled scientists.  I am excited that we will be able to tap into this talent pool and to strengthen our research through this initiative. It is delightful to see that the Hong Kong ITC is taking the lead to support biotechnology development in the Region and that Kinex is able to be part of this.  I strongly believe that this project will generate further scientific excitement around the application of the novel non-absorbable P-glycoprotein inhibitor, HM30181A, in the oncology field," declared David Hangauer, CSO of Kinex.

Dr. Jeewoong Son, Senior VP and Head of Innovation R&D at Hanmi added, "As a collaborator, we are excited to see Kinex strengthen their presence in Asia (Hong Kong). Our partnership with Kinex has been extremely productive and rewarding and we will continue to support Kinex in further expanding the use of the Orascovery platform in innovative drug formulation development."

Kinex has establish a wholly owned subsidiary Kinex Pharmaceuticals (Hong Kong) Limited to carry out this collaborative work.

About Kinex:

Founded in 2004, Kinex is led by a strong, experienced Management Team and Board of Directors with a track record of achieving value-creating milestones and cumulative experience of over 250 years in both the pharmaceutical and biotechnology industries. This includes the filing of more than 11 NDAs and 20 INDs with the Food and Drug Administration and the development of more than 10 marketed products, including a number of blockbusters. Kinex has utilized the proprietary platform technologies Mimetica™, Opal™, and Orascovery™ to discover new compounds and to build a pipeline of drug candidates with unique mechanisms that address unmet medical needs with large market potential. With offices in both Buffalo, NY and Hong Kong, Kinex has numerous existing partnerships in Asia and New Zealand, as well as investors throughout the United States and Asia.

For Kinex inquiries please contact:

Mr. Patrick Gallagher
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
pgallagher@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
2. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
3. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
4. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
5. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
6. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
7. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
8. Kinex Pharmaceuticals Receives Substantial Strategic Investment
9. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
10. Avion Pharmaceuticals, LLC, receives top accolades for trade and marketing achievements at the 11th Annual American Business Awards (The "Stevie Awards")
11. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
Breaking Medicine News(10 mins):